Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Core Scientific Inc’s stock clocked out at $21.8, up 0.28% from its previous closing price of $21.74. In other words, the price has increased by $0.28 from its previous closing price. On the day, 15.14 million shares were traded. CORZ stock price reached its highest trading level at $22.49 during the session, while it also had its lowest trading level at $21.305.
On October 23, 2025, Roth Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $23.50.
B. Riley Securities Upgraded its Neutral to Buy on October 22, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 25 ’25 when DUCHENE TODD M sold 7,759 shares for $12.39 per share. The transaction valued at 96,142 led to the insider holds 2,049,689 shares of the business.
DUCHENE TODD M bought 7,759 shares of CORZ for $96,142 on Jun 25 ’25. On Jun 06 ’25, another insider, Becker Todd A, who serves as the Former Director of the company, bought 195,687 shares for $12.28 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORZ now has a Market Capitalization of 6759336448 and an Enterprise Value of 7467743232. As of this moment, Core’s Price-to-Earnings (P/E) ratio for their current fiscal year is 156.50, and their Forward P/E ratio for the next fiscal year is 143.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.23. Its current Enterprise Value per Revenue stands at 22.346 whereas that against EBITDA is -99.269.
Stock Price History:
The Beta on a monthly basis for CORZ is 6.55, which has changed by 0.32077765 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, CORZ has reached a high of $23.63, while it has fallen to a 52-week low of $6.20. The 50-Day Moving Average of the stock is 24.10%, while the 200-Day Moving Average is calculated to be 69.63%.
Shares Statistics:
It appears that CORZ traded 16.70M shares on average per day over the past three months and 21652300 shares per day over the past ten days. A total of 308.38M shares are outstanding, with a floating share count of 290.89M. Insiders hold about 6.18% of the company’s shares, while institutions hold 97.97% stake in the company. Shares short for CORZ as of 1760486400 were 58699424 with a Short Ratio of 3.51, compared to 1757894400 on 55459885. Therefore, it implies a Short% of Shares Outstanding of 58699424 and a Short% of Float of 19.209999.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.12, with high estimates of $0.12 and low estimates of $0.12.
Analysts are recommending an EPS of between $1.09 and -$1.94 for the fiscal current year, implying an average EPS of -$1.35. EPS for the following year is $0.19, with 13.0 analysts recommending between $0.71 and -$0.47.
Revenue Estimates
In. The current quarter, 13 analysts expect revenue to total $127.92M. It ranges from a high estimate of $154.1M to a low estimate of $85.6M. As of. The current estimate, Core Scientific Inc’s year-ago sales were $94.92MFor the next quarter, 13 analysts are estimating revenue of $164.74M. There is a high estimate of $209.17M for the next quarter, whereas the lowest estimate is $109.23M.
A total of 14 analysts have provided revenue estimates for CORZ’s current fiscal year. The highest revenue estimate was $436.3M, while the lowest revenue estimate was $324.85M, resulting in an average revenue estimate of $376.06M. In the same quarter a year ago, actual revenue was $510.67MBased on 17 analysts’ estimates, the company’s revenue will be $797.13M in the next fiscal year. The high estimate is $1.14B and the low estimate is $424M.
